| Literature DB >> 30482773 |
Li Peng1,2,3, Binyuan Jiang1,4, Xiaoqing Yuan2,5, Yuntan Qiu2,3, Jiangyun Peng2,3, Yongsheng Huang2,3, Chaoyang Zhang1, Yin Zhang2,3, Zhaoyu Lin2,6, Jinsong Li2,6, Weicheng Yao2,3, Weixi Deng2,3, Yaqin Zhang1, Meng Meng2,3, Xi Pan7, Chunquan Li8, Dong Yin2,3, Xinyu Bi9, Guancheng Li10,11, De-Chen Lin12,3.
Abstract
Hepatocellular carcinoma (HCC) is one of the most dominant causes of neoplasm-related deaths worldwide. In this study, we identify and characterize HCCL5, a novel cytoplasmic long noncoding RNA (lncRNA), as a crucial oncogene in HCC. HCCL5 promoted cell growth, G1-S transition, invasion, and metastasis while inhibiting apoptosis of HCC cells both in vitro and in vivo. Moreover, HCCL5 was upregulated in TGF-β1-induced classical epithelial-to-mesenchymal transition (EMT) models, and this lncRNA in turn accelerated the EMT phenotype by upregulating the expression of transcription factors Snail, Slug, ZEB1, and Twist1. HCCL5 was transcriptionally driven by ZEB1 via a super-enhancer and was significantly and frequently overexpressed in human HCC tissues, correlating with worse overall survival of patients with HCC. Together, this study characterizes HCCL5 as a super-enhancer-driven lncRNA promoting HCC cell viability, migration, and EMT. Our data also suggest that HCCL5 may serve as a novel prognostic biomarker and therapeutic target in HCC. SIGNIFICANCE: These findings identify the lncRNA HCCL5 as a super-enhancer-driven oncogenic factor that promotes the malignancy of hepatocellular carcinoma. ©2018 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30482773 DOI: 10.1158/0008-5472.CAN-18-0367
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701